Literature DB >> 15717264

HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia.

Serena S Spudich1, Wei Huang, Annelie C Nilsson, Christos J Petropoulos, Teri J Liegler, Jeannette M Whitcomb, Richard W Price.   

Abstract

BACKGROUND: Chemokine receptors serve as coreceptors for human immunodeficiency virus type 1 (HIV-1) entry, influence cell tropism, and may critically determine central nervous system infection pathogenesis. Using an in vitro functional entry assay, we examined utilization of 2 principal coreceptors in cerebrospinal fluid (CSF) and plasma in 46 subjects.
METHODS: Paired CSF and plasma samples were selected from subjects with a range of CD4 T cell counts. Amplified populations of env sequences were characterized as using CCR5 (R5), CXCR4 (X4), or both receptors (R5+X4). Individual clones derived from 3 subjects were analyzed for viral tropism and phylogeny.
RESULTS: CSF and plasma pairs were mainly concordant for R5 (36/46) or R5+X4 (5/46) viruses. However, 5 pairs were discordant, 2 of which had the R5+X4 phenotype in CSF despite having the R5 phenotype in plasma. Although R5+X4 tropism was associated with advanced immunodeficiency, all 4 subjects with acquired immunodeficiency syndrome dementia complex had R5 tropism in CSF. Clones derived from R5+X4-tropic populations revealed mixtures of R5 and X4 viruses and viruses able to utilize either coreceptor, suggesting both virus exchange between compartments and autonomous CSF virus evolution.
CONCLUSIONS: Although R5 viruses predominate in the CSF, HIV-1 populations able to utilize CXCR4 are also present. Discordant tropism in CSF and plasma may have implications for R5 inhibitor therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15717264     DOI: 10.1086/428095

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

1.  Interruptions of antiretroviral therapy in human immunodeficiency virus infection: are they detrimental to neurocognitive functioning?

Authors:  Jose A Muñoz-Moreno; Carmina R Fumaz; Anna Prats; Maria J Ferrer; Eugènia Negredo; Núria Pérez-Alvarez; José Moltó; Guadalupe Gómez; Maite Garolera; Bonaventura Clotet
Journal:  J Neurovirol       Date:  2010-05       Impact factor: 2.643

2.  Biomarkers of HIV-1-associated neurocognitive disorders: challenges of proteomic approaches.

Authors:  Pawel Ciborowski
Journal:  Biomark Med       Date:  2009-12       Impact factor: 2.851

3.  Individuals with HIV-1 Subtype C Infection and Cryptococcal Meningitis Exhibit Viral Genetic Intermixing of HIV-1 Between Plasma and Cerebrospinal Fluid and a High Prevalence of CXCR4-Using Variants.

Authors:  Katlego Sojane; Richard T Kangethe; Christina C Chang; Mahomed-Yunus S Moosa; Sharon R Lewin; Martyn A French; Thumbi Ndung'u
Journal:  AIDS Res Hum Retroviruses       Date:  2018-05-23       Impact factor: 2.205

4.  Raltegravir resistance in the cerebrospinal fluid.

Authors:  B Mora-Peris; N E Mackie; D Suan; D A Cooper; B J Brew; A Winston
Journal:  Infection       Date:  2013-02-03       Impact factor: 3.553

5.  The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia.

Authors:  Rebecca L Dunfee; Elaine R Thomas; Paul R Gorry; Jianbin Wang; Joann Taylor; Kevin Kunstman; Steven M Wolinsky; Dana Gabuzda
Journal:  Proc Natl Acad Sci U S A       Date:  2006-10-02       Impact factor: 11.205

6.  Compartmentalized human immunodeficiency virus type 1 present in cerebrospinal fluid is produced by short-lived cells.

Authors:  Patrick R Harrington; David W Haas; Kimberly Ritola; Ronald Swanstrom
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

7.  HIV coreceptor tropism in paired plasma, peripheral blood mononuclear cell, and cerebrospinal fluid isolates from antiretroviral-naïve subjects.

Authors:  S G Parisi; C Andreoni; L Sarmati; C Boldrin; A R Buonomini; S Andreis; R Scaggiante; M Cruciani; O Bosco; V Manfrin; G d'Ettorre; C Mengoli; V Vullo; G Palù; M Andreoni
Journal:  J Clin Microbiol       Date:  2011-03-02       Impact factor: 5.948

Review 8.  CCR5 blockade for neuroinflammatory diseases--beyond control of HIV.

Authors:  Guillaume Martin-Blondel; David Brassat; Jan Bauer; Hans Lassmann; Roland S Liblau
Journal:  Nat Rev Neurol       Date:  2016-01-18       Impact factor: 42.937

9.  Mode of coreceptor use by R5 HIV type 1 correlates with disease stage: a study of paired plasma and cerebrospinal fluid isolates.

Authors:  Ulf Karlsson; Liselotte Antonsson; Johanna Repits; Patrik Medstrand; Christer Owman; Karin Kidd-Ljunggren; Lars Hagberg; Bo Svennerholm; Marianne Jansson; Magnus Gisslén; Bengt Ljungberg
Journal:  AIDS Res Hum Retroviruses       Date:  2009-12       Impact factor: 2.205

Review 10.  Antiretroviral therapy and central nervous system HIV type 1 infection.

Authors:  Richard W Price; Serena Spudich
Journal:  J Infect Dis       Date:  2008-05-15       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.